| Literature DB >> 35739896 |
Nikolaos Tsekouras1, Zoi Athanasakopoulou2, Celia Diezel3,4, Polychronis Kostoulas5, Sascha D Braun3,4, Marina Sofia2, Stefan Monecke3,4, Ralf Ehricht3,4, Dimitris C Chatzopoulos5, Dominik Gary6, Domenique Krähmer6, Vassiliki Spyrou7, Georgios Christodoulopoulos1, Charalambos Billinis2,5, Vasileios G Papatsiros1.
Abstract
This study aimed to estimate the prevalence of extended-spectrum β-lactamase-producing (ESBL) bacteria in swine. Thus, 214 fecal samples were collected from suckling and weaned piglets from 34 farms in Greece (out of an overall population of about 14,300 sows). A subset of 78 (36.5%) ESBL producers were identified as E. coli (69/78, 88.5%), K. pneumoniae spp. pneumoniae (3.8%), P. mirabilis (5.1%), E. cloacae complex (1.3%) and S. enterica spp. diarizonae (1.3%). Resistance to at least one class of non-β-lactam antibiotics was detected in 78 isolates. Among the E. coli strains, resistance was identified with regard to aminoglycosides (n = 31), fluoroquinolones (n = 49), tetracycline (n = 26) and trimethoprim/sulfamethoxazole (n = 46). Of the three K. pneumoniae spp. pneumoniae, two displayed resistances to aminoglycosides and all were resistant to fluoroquinolones, tetracyclines and trimethoprim/sulfamethoxazole. As for the four P. mirabilis isolates, three had a resistant phenotype for aminoglycosides and all were resistant to imipenem, fluoroquinolones, tetracyclines and trimethoprim/sulfamethoxazole. Molecular characterization of the isolates revealed the presence of CTX-M, SHV and TEM genes, as well as of genes conferring resistance to fluoroquinolones, aminoglycosides, sulfonamides, trimethoprim, macrolides and colistin. High levels of antimicrobial resistance (AMR) were demonstrated in Greek swine herds posing a concern for the efficacy of treatments at the farm level as well as for public health.Entities:
Keywords: ESBL-producing Enterobacteriaceae; Greece; antimicrobial resistance; multidrug resistance genes; pigs
Year: 2022 PMID: 35739896 PMCID: PMC9219512 DOI: 10.3390/ani12121560
Source DB: PubMed Journal: Animals (Basel) ISSN: 2076-2615 Impact factor: 3.231
Geographic origin and capacity of study’s farms.
|
|
|
|
|
| |||||
|
|
|
|
|
|
|
| |||
| Northern Greece | 4 | 1640 | 0 | 2 | 1 | 1 | 0 | 8 | 19 |
| Central Greece | 13 | 3710 | 4 | 2 | 3 | 4 | 0 | 24 | 44 |
| Western Greece | 10 | 5790 | 0 | 4 | 2 | 2 | 2 | 22 | 42 |
| Southern Greece | 7 | 3190 | 0 | 4 | 2 | 0 | 1 | 19 | 36 |
| Total | 34 | 14,300 | 4 | 12 | 8 | 7 | 3 | 73 | 141 |
Criteria for farms selection.
| Criteria | Farms | Sows | Weaners |
|---|---|---|---|
| Capacity | Minimum 50 sows | ||
| Type of farm | Exclusive farrow-to-finish | ||
| Antiparasitic treatment | Antiparasitic treatment (IM) | ||
| Vaccination | Aujeszky’s disease virus | Porcine Circovirus type 2 | |
| Diet | Home-made diets (mixed corn/barley/wheat–soybean-based meal) balanced in dietary nutrients (essential amino acids, minerals and vitamins) 1 | ||
| Toxin binders | Systematically used in the feed during gestation and lactation | Systematically used in the feed | |
| Routine program for metaphylaxis of PPDS | Amoxicillin (IM) | ||
| Routine program of | Amoxicillin via feed for the first 10 days after weaning | ||
1 According to Nutrient Requirements of Swine (NRC) [29].
Isolation and identification of ESBL-producing bacteria from pig samples.
| Bacterial Species | Percentage of Isolates ( | Percentage of ESBL-Producing Isolates ( |
|---|---|---|
|
| 32.2 ( | 88.5 ( |
| 1.4 ( | 3.8 ( | |
|
| 1.9 ( | 5.1 ( |
|
| 0.5 ( | 1.3 ( |
| 0.5 ( | 1.3 ( | |
| Total | 36.5 ( | 100 ( |
1 Number of fecal samples tested; 2 Number of isolated ESBL-producing bacteria.
Figure 1Bar plot showing the percentage of AMR of E. coli, E. cloacae complex, K. pneumoniae, P. mirabilis and Salmonella spp. to a range of antibiotics; AMP, AMC, TCC, CEX, CF, CEP, CEF, CEQ, IMI, GEN, NEO, FLU, ENR, MRX, TET, SXT and FLO. The values varied from 0.00 to 1.00; 0.00 indicates resistance and 1.00 susceptibility. R/I: Resistance/Intermediate results; S: Susceptibility; AMP: ampicillin, AMC: amoxicillin/clavulanic acid, TCC: ticarcillin/clavulanic acid, CEX: cefalexin, CF: cefalotin, CEP: cefoperazone, CEF: ceftiofur, CEQ: cefquinome, IMI: imipenem, GEN: gentamicin, NEO: neomycin, FLU: flumequine, ENR: enrofloxacin, MRX: marbofloxacin, TET: tetracycline, FLO: florfenicol, PMB: polymyxin B, SXT: trimethoprim/sulfamethoxazole (SXT).
Figure 2Principal component analysis (PCA) on co-resistances. Antibiotics are represented by vectors (arrows). Two vectors of antibiotics pointing in the same direction is an indication of a positive correlation between them; when we observe AMR in one antibiotic, we are expecting the development of AMR in the other one. An angle of 180 degrees between the vectors of two antibiotics is an indication of a negative correlation between them; when we observe AMR in one, we are not expecting the development of AMR in the other. A 90-degree angle between the vectors of two antibiotics indicates no relationship between them toward the developing AMR. The longer the vectors, the greater the intensity of this relationship. AMP: ampicillin, AMC: amoxicillin/clavulanic acid, TCC: ticarcillin/clavulanic acid, CEX: cefalexin, CF: cefalotin, CEP: cefoperazone, CEF: ceftiofur, CEQ: cefquinome, IMI: imipenem, GEN: gentamicin, NEO: neomycin, FLU: flumequine, ENR: enrofloxacin, MRX: marbofloxacin, TET: tetracycline, FLO: florfenicol, PMB: polymyxin B, SXT: trimethoprim/sulfamethoxazole (SXT).
Figure 3Box and whisker plot showing the prevalence of AMR (y axis) of ESBL-producing E. coli, E. cloacae complex, K. pneumoniae, P. mirabilis and Salmonella spp. (x-axis). The bold line shows the median value, while the length of the box represents the interquartile range.
Resistance genes detected among the ESBL-producing Enterobacteriaceae.
| Resistance Genes | Number of Isolates | ||||
|---|---|---|---|---|---|
|
|
|
| |||
|
| 52 | 2 | - | - | - |
|
| 6 | 1 | 3 | - | - |
|
| 6 | - | 1 | - | - |
|
| 3 | 2 | - | - | - |
|
| 38 | 1 | 3 | 1 | - |
|
| 18 | - | - | - | - |
|
| 1 | - | - | - | - |
|
| 17 | - | 4 | - | - |
|
| 1 | - | - | - | - |
|
| 36 | 1 | 3 | 1 | - |
|
| 21 | - | 1 | 1 | - |
|
| 14 | - | - | 1 | - |
|
| 21 | 1 | 1 | 1 | - |
|
| 27 | - | - | - | - |
|
| 7 | - | - | - | - |
|
| 2 | - | 3 | - | - |
|
| 1 | - | 3 | - | - |
|
| 29 | 3 | - | 1 | - |
|
| 2 | - | - | - | - |
|
| 4 | - | - | - | - |
|
| 18 | 2 | 3 | - | - |
|
| 38 | 3 | 4 | 1 | - |
|
| 17 | - | - | 1 | - |
|
| 13 | 1 | 3 | - | - |
|
| 42 | - | 2 | - | 1 |
|
| 4 | 1 | - | - | - |
|
| 12 | - | - | 1 | - |
|
| 2 | - | - | - | - |
|
| 12 | 1 | - | - | - |
|
| 1 | - | - | - | - |
|
| 15 | 1 | 1 | 1 | - |
|
| 4 | - | - | - | - |
|
| 6 | - | - | 1 | - |
|
| 1 | - | - | - | - |
|
| 3 | - | - | 1 | - |
|
| 12 | - | - | - | - |
|
| 16 | - | - | - | - |
|
| 20 | 2 | - | - | - |
|
| 7 | 1 | 3 | - | - |
|
| 30 | 3 | - | 1 | - |
|
| 1 | 3 | - | - | - |
|
| 1 | 3 | - | - | - |
Associations of ESBL-producing Enterobacteriaceae with herd characteristics and administration of antibiotics.
| ESBL-Producing | Logistic Regression | |||
|---|---|---|---|---|
| Parameter | Category | Estimate (95% CI) | ||
|
| PMLs | 0 | 1 | |
| 1 | 0.25 (0.07; 0.84) | 0.0215 | ||
|
| Size | - | 85.86 (4.02; 6620.06) | 0.00648 |
Association of AMR with herd characteristics and administration of antibiotics.
| Antibiotic | Logistic Regression | |||
|---|---|---|---|---|
| Parameter | Category | Estimate (95% CI) | ||
| AMP | Size | 48.72 (3.21; 1955.14) | 0.0171 | |
| AMC | Size | 31.38 (5.3; 290.81) | <0.005 | |
| IMI | Size | 33.09 (2.16; 1454.48) | 0.008 | |
| GEN | PMLs | 0 | 1 | |
| 1 | 0.15 (0.02; 0.58) | 0.016 | ||
| Quinolones | 0 | 1 | ||
| 1 | 13.14 (2.46; 243.71) | 0.015 | ||
| NEO | PMLs | 0 | 1 | |
| 1 | 0.19 (0.03; 1.05) | 0.028 | ||
| TETs | 0 | 1 | ||
| 1 | 7.7 (1.62; 59.44) | 0.009 | ||
| MRX | TETs | 0 | 1 | |
| 1 | 14.45 (0.96; 5.59) | 0.011 | ||
| ENR | Cephalosporins | 0 | 1 | |
| 1 | 3.49 (1.07; 14.84) | 0.045 | ||